PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-45 lat
- •Rak endometrium w wczesnym stadium (IA)
- •Potwierdzony nowotwór złośliwy macicy G1-G2
- •Stwierdzone zaburzenia w genach odpowiedzialnych za naprawę DNA (MMRd)
- •Silne pragnienie posiadania dzieci w przyszłości
- •Podpisana zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Zaawansowany nowotwór (stadium IB lub wyższe)
- •Nowotwór słabo zróżnicowany (G3) lub inny typ histologiczny
- •Jednoczesne występowanie innego nowotworu
- •Przeciwwskazania do zachowawczego leczenia lub stosowania leków
- •Przeciwwskazania do ciąży lub niezdolność do ciąży i porodu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 45 Years
- Last updated (source)
- August 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
Jianliu Wang, Professor
Yiqin Wang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.